Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00645983 · ClinicalTrials.gov registry record · Phase 4
Chamomile Therapy for Generalized Anxiety
A Phase 4 study of Generalized Anxiety Disorder, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 61
- Enrollment target
- 1
- Study location
NCT00645983 is a Phase 4 study of Generalized Anxiety Disorder that has completed, run by University of Pennsylvania. The registered enrollment target is 61 participants, below the 214-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00645983, a Phase 4 study of Generalized Anxiety Disorder, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 61 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will determine the effectiveness of chamomile extract for treating generalized anxiety disorder. Study hypotheses: 1)Chamomile extract will have a superior anti-anxiety effect compared to placebo. 2)Chamomile will have a comparable safety profile to that of placebo.
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Chamomile Extract
Study Locations (1)
Pennsylvania
- Depression Research Unit, Universityof Pennsylvania School of Medicine - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2005-10 |
| Est. Completion | 2008-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00645983
The ClinicalTrials.gov registry entry for NCT00645983 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 214-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target (71% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Generalized Anxiety Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00645983 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00645983 about?
NCT00645983 is a clinical study titled "Chamomile Therapy for Generalized Anxiety". This study will determine the effectiveness of chamomile extract for treating generalized anxiety disorder. Study hypotheses: 1)Chamomile extract will have a superior anti-anxiety effect compared to placebo. 2)Chamomile will have a comparable safety profile to that of placebo.
What is the current status of trial NCT00645983?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 61 participants. The study started on 2005-10. Estimated completion is 2008-01.
What conditions does trial NCT00645983 study?
This clinical trial studies the following conditions: Generalized Anxiety Disorder.
What interventions are being tested in trial NCT00645983?
The interventions under investigation include: Placebo (OTHER), Chamomile Extract (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00645983?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00645983 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Anxiety Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Brain Stimulation & Generalized Anxiety Study
ACTIVE NOT RECRUITING · Phase 4
-
Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)
COMPLETED · Phase 4
-
Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects
COMPLETED · Phase 4
-
A Study of Risperidone Monotherapy in Bipolar Anxiety
COMPLETED · Phase 4
-
Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder
COMPLETED · Phase 4
-
Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.